Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-08-29
2009-12-22
Mondesi, Robert B (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S244100, C530S350000, C536S023700, C435S252300
Reexamination Certificate
active
07635482
ABSTRACT:
Streptococcusproteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy ofstreptococcusinfection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detectingstreptococcusbacterial infection.
REFERENCES:
patent: 4242501 (1980-12-01), Cano et al.
patent: 6503511 (2003-01-01), Wizemann et al.
patent: 6573082 (2003-06-01), Choi et al.
patent: 6582706 (2003-06-01), Johnson et al.
patent: 6699703 (2004-03-01), Doucette-Stamm et al.
patent: 6800744 (2004-10-01), Doucette-Stamm et al.
patent: 6833356 (2004-12-01), Koenig et al.
patent: 7056510 (2006-06-01), Choi et al.
patent: 7074415 (2006-07-01), Hamel et al.
patent: 7122194 (2006-10-01), Johnson et al.
patent: 2003/0138447 (2003-07-01), Wizemann et al.
patent: 2003/0232976 (2003-12-01), Hamel et al.
patent: 2004/0005331 (2004-01-01), Johnson et al.
patent: 2004/0052781 (2004-03-01), Johnson et al.
patent: 2004/0081662 (2004-04-01), Hermand et al.
patent: 2006/0051361 (2006-03-01), Laferriere et al.
patent: 2006/0263846 (2006-11-01), Meinke et al.
patent: 0837130 (1998-04-01), None
patent: WO94/21685 (1994-09-01), None
patent: WO96/40928 (1996-12-01), None
patent: WO98/18930 (1998-05-01), None
patent: WO98/18931 (1998-05-01), None
patent: WO99/15675 (1999-04-01), None
patent: WO99/42588 (1999-08-01), None
patent: WO00/06737 (2000-02-01), None
patent: WO00/06738 (2000-02-01), None
patent: WO00/17370 (2000-03-01), None
patent: WO00/37105 (2000-06-01), None
patent: WO00/39299 (2000-07-01), None
patent: WO00/76540 (2000-12-01), None
patent: WO01/14421 (2001-03-01), None
patent: WO01/98334 (2001-12-01), None
patent: WO02/077021 (2002-10-01), None
patent: WO2004/092209 (2004-10-01), None
Adamou, John E. et al, Infection and Immunity, vol. 69(2), pp. 949-958, Feb. 2001, Identificaiton and Characterization of a Novel Family of Pneumococcal proteins that are protective against Sepsis.
Hamel, Josee et al, Infection and Immunity, May 2004, vol. 72(5), pp. 2659-2670.
Adamou, John E. et al, Infection and Immunity, vol. 69(3), pp. 949-958, Feb. 2001.
Adamou et al., “Identification and Characterization of a Novel Family of Pneumococcal Proteins that are Protective against Sepsis,”Infection and Immunity, pp. 949-958, Feb. 2001.
Boslego et al., Chapter 17: ‘Gonorrhea Vaccines’,Vaccines and ImmunotherapyPergamon Press, pp. 211-223, 1991.
Bolton et al., “Use of the Surface Proteins GapC and Mig ofStreptococcus dysgalactiaeas Potential Protective Antigens against Bovine Mastitis,”Canadian Journal of Microbiology50(6):423-32, Jun. 2004 (abstract only).
Briles et al., “Immunization of Humans and Recombinant Pneumococcal Surface Protein A (rPspA) Elecits Antibodies that Passively Protect Mice from Fatal Infection withStreptococcus pneumoniaeBearing Heterologous PspA,”Journal of Infectious Disease 182, pp. 1694-1701, Dec. 2000.
Briles et al., “Intranasal Immunization of Mice with a Mixture of the Penumococcal Proteins PsaA and PspA is Highly Protective against Nastopharyngeal Carriage ofStreptococcus pneumoniae,” Infection and Immunity 68(2):796-800, Feb. 2000.
Creighton,Proteins: Structures and Molecular Principles, 1984, pp. 314-315.
Creighton,Protein Structure: A Practical Approach, 1989, pp. 184-186.
Ellis et al., “New Technologies for Making Vaccines,”Vaccines, W. B. Sanders Co., 1988, Chapter 29, pp. 568-575.
Hernandez et al., “Antigenicity of Chimeric Synthetic Peptides based on HTLV-1 Antigens and the Impact of Epitope Orientation,”Biochemical and Biophysical Research Communications 276(3):1085-1088, Oct. 2000.
Kurstak, “Recent Progress in Vaccines Development and New Trends in Immunisation,”Vaccine 19:2198-2200, 2001.
Nosoh et al., “Protein Stability and Stabilization through Protein Engineering,” 197-217, 1991.
Oishi et al., “The Effect of Amino Acid Spacers on the Antigenicity of Dimeric Peptide-Inducing Cross-Reacting Antibodies t a Cell Surface Protein Antigen ofStreptococcusmutans,”Oral Microbiology Immunology 16:40-44, 2001.
Okamoto et al., “Vaccination with Formali-Inactivated Influenza Vaccine Protects Mice against Legal InfluenzaStreptococcusPyogenes Superinfection,”Vaccine 22:2887-2893, 2004.
Oli et al., “Redirecting the Humoral Immune Response againstStreptococcusMutans Antigen P1 with Monoclonal Antibodies,”Infection and Immunity, 6951-6960, Dec. 2004.
Orihuela et al., “Organ-Specific Models ofStreptococcus pneumoniaeDisease,”Scandinavian Journal of Infectious Diseases 35(9):647-652, 2003.
Partidos et al., “The Influence of Orientation and Number of Copies of T and B Cell Epitopes on the Specificity and Affinity of Antbodies Induced by Chimeric Peptides,”European Journal of Immunology 22:2675-2680, 1992.
Sa-Leao et al., “Abstracts of the General Meeting of the American Society for Microbiology,” May 20-24, 2001.
Spellerberg et al., “LMB, a Protein with Similarities to the Lral Adhesin Family, Mediates Attachment ofStreptococcus agalactiaeto Human Laminin,”Infection and Immunity, 871-878, Feb. 1999.
Swildens et al., “Intestinal Translocation ofStreptococcusSuits Type 2EF+in Pigs,”Veterinary Microbiology 103:29-33, 2004.
Whittam et al., “Inferences from Whole-Genome Sequences of Bacterial Pathogens,”Current Opinion in Genetics and Development 12(6):719-725, Dec. 2002.
Wizemann et al., “Use of a Whole Genome Approach to Identify Vaccine Molecules Affording Protection againstStreptococcus pneumoniaeInfection,”Infection and Immunity, 1593-1596, Mar. 2001.
Zhang et al., “Recominant RhpA Protein, a Unique Histidine Motif-Containing Protein fromStreptococcus pneumoniae, Protects Mice against Intranasal Pneumococcal Challenge,”Infection and Immunity, 3827-3836, Jun. 2001.
Zysk et al., “Detection of 23 Immunogenic Pneumococcal Proteins using Convalescent-Phase Serum,”Infection and Immunity 68(6)3740-3743, Jun. 2000.
PCT Notification of Transmittal of The International Search Report or The Declaration dated Jul. 24, 2000.
Hopp, “Retrospective: 12 Years of Antigenic Determinant Predictions, and More,”Peptide Research 6(4):183-190, 1993.
Hofmann et al., “On the theoretical prediction of protein antigenic determinants from amino acid sequences,”Biomed. Biochim. Acta 46(11):855-866, 1987.
Jameson et al., “The antigenic index: a novel algorithm for predicting antigenic determinants,”Computer Application Bioscience 4(1):181-186, 1988.
Kolaskar et al., “A semi-empirical method for prediction of antigenic determinants on protein antigens,”FEBS 276(1,2):172-174, 1990.
Lipman et al., “Monoclonal Versus Polyclonal Antibodies: Distinguishing Characteristics, Applications, and Information Resources,”ILAR Journal 46(3):258-268, 2005.
Martin et al., “Bioinformatics tools for identifying class I-restricted epitopes,”Methods 29:289-298, 2003.
Menendez-Arias et al., “A BASIC microcomputer program for prediction of B and T cell epitopes in proteins,”Comput. Appl. Biosci. 6(2):101-105, 1990.
Roitt et al.,Immunology, 4thEdition, 1998, pp. 7.7-7.8, Mosby, London.
Thornton et al., “Location of ‘continuous’ antigenic determinants in the protruding regions of proteins,”EMBO Journal 5(2):409-413, 1986.
Tong et al., “Methods and protocols for prediction of immunogenic epitopes,”Briefings in Bioinformatics 8(2):96-108, 2006.
Wan et al., “Epitope Map for a Growth Hormone Receptor Agonist Monoclonal Antibody, MAb 263,”Molecular Endocrinology 17(11):2240-2250, 2003.
Swiss Prot Accession No. Q9ANY1—Strpn.
Brodeur Bernard R.
Charland Nathalie
Hamel Josee
Martin Denis
Pineau Isabelle
ID Biomedical Corporation
Mondesi Robert B
Portner Ginny
Seed IP Law Group PLLC
LandOfFree
Streptococcus antigens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Streptococcus antigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Streptococcus antigens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4093605